AstraZeneca Reports Q3 Revenue of $16.21 Billion; Oncology Rises 17%
The headline also reports a decline for Farxiga and an Etcamah miss; it does not specify what Etcamah missed.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.